



Overview

- · Pathophysiology of trauma and shock
- Traditional trauma management
- · Current trauma management
- · Massive transfusion protocol
- · Balanced blood product therapy
- · Antifibrinolytics and components



US Injury Incidence

- In the USA, 36,000,000/y (1/7) suffer significant injury
- 27,000,000 injury-related doctor or hospital visits
- 1,700,000 injury-related hospital admissions
- 1,000,000 are transferred to trauma centers
- 10,000 require massive transfusion
- Extent of injury is determined by whole body CT scan or focused abdominal sonography for trauma (FAST)

Zimrin AB, Bai Y, Holcomb JB, Hess JR. Hemorrhage control and thrombosis following severe injury. In Kitchens CS, Kessler CM, Konkle BA, Consultative Hemostasis and Thrombosis. Elsevier, 2013



Death by Trauma

- · Unintended or intentional injury is the most common cause of death in N Americans age 1-45
 - 93,000/y in the USA, up 20% since 2005
 - 3,000,000/y worldwide, exceeded only by AIDS deaths
- · 50% of trauma deaths are caused by neurological displacement and occur before reaching hospital
- 20,000 die in hospital of exsanguination in 48 h
 - 30-35% with blood loss & uncompensated shock expire
 - 3-4,000 of US hemorrhage deaths are preventable
 - Coagulopathy, failure to achieve hemostasis


Rhee P, Joseph B, Pandit V, et al. Increasing trauma deaths in the United States. Ann Surg 2014;260: 13-21.

Years of Potential Life Lost (YPLL) Before Age 65

Cause of Death		YP	LL
F	Percent		
All Caus	es	948,426	100.0%
Unintent	ional Injury	199,903	21.1%
Suicide		52,265	5.5% - 31.7 %
Homicide	е	48,190	5.1%
Malignar	nt Neoplasms	137,221	14.5%
Heart Disease		107,009	11.3%
Perinatal Period		75,496	8.0%
Congenital Anomalies		43,615	4.6%
Cerebrovascular		21,817	2.3%
HIV		21,508	2.3%
Liver Disease		21,352	2.3%
All Other	'S	220,050	23.2%
m\			National Center for Injury
Prevention and Control. Web-based Injury Statistics Query and Reporting be Fritsma Factor System (WISQARS) accessed 5-19-14. www.cdc.gov/injury/wisgars			

ACTOR Diabeter Meliitas 6,062 Liver Disease 2,582 Diabetes Melitius 709 Diabetos Melitius 1,999 Cerebro-rescalar 5.349 Corebro-vescular 11.727 Diabetes Melitus HEV 583 Inflanca & Presmonia 41 Contro-vasculor 579 Influenza & Processoria 2,731 HW 1,174 Nophritis 39,957 Nophritis 45,146 Septicemia 2,514






THE FRITSMA FACTOR Your Interactive Hemostasis Resource

24-YO ♂, GSW in ED, 2008

A 24-YO male arrived in the ED with a shotgun wound causing massive abdominal trauma. He had received three units of Dextran® balanced 5% glucose-electrolyte crystalloid in transit to achieve fluid resuscitation but was hemorrhaging. ED personnel ordered and administered four RBC units. Upon the second RBC four-unit batch order the transfusion service director recommended one plasma and one pheresis platelet concentrate. After 8 RBCs, she ordered 1 more plasma and 1 more platelet, but the patient was still bleeding.

PT: 20.8 s (MRI 12.9); PTT: 82.5 s (MRI 30.1) FG: 130 mg/dL (RI 225–498); PLTs: 70,000/uL (RI 150– 450,000)

Fritsma Factor Previous Massive Tx Protocol





Traditional TIC Management

- · If no coagulopathy is suspected...
 - Ligate and treat with crystalloids and RBCs
 - Discourage plasma and platelets
- · If coagulopathy is suspected...
 - Plasma to replenish multiple coagulation factors
 - Platelet concentrate for thrombocytopenia
 - Coagulation factor concentrates: VIII, IX
 - Replenish FG with CRYO or RiaSTAP (2009)
 - Repletiisti FG with CRTO of Riastar (200
 - Activated PCC (FEIBA)

Four-factor PCC (KCentra)
 NovoSeven® recombinant activated factor VII

 Previous Massive Tx Protocol



American Society of Anesthesiologists 2006 Practice Guidelines



- Use no plasma to augment volume, use colloid or crystalloid expanders (5% dextrose: Dextran[®])
 - Plasma only if microvascular bleeding...
 - And PT >1.5X "normal" or PTT >2X "normal"
- Use RBCs when HGB <6 g/dL
- "Usually" give platelets if <50,000/uL, unless...
 - Limited blood loss is anticipated based on type of surgery
 - Thrombocytopenia is associated with HIT, ITP, or TTP, where platelets may be ineffective

Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105: 198–208.

The Fritsma Factor

Previous Massive Tx Protocol

12

THE FRITSMA FACTOR Your Interactive Hemostasis Resource


2004 Baghdad Case

- An IED-injured US soldier received 18 RBC units and died of dilutional coagulopathy before plasma could be thawed
- Surgeons and BB director agreed to keep 4 units of thawed AB plasma available at all times
- Initiated 1:1 plasma/RBC Rx; improved resuscitation, reduced hemorrhage, added PLT concentrate 2006
- Reduced crystalloids (Dextran, 5% glucose), reduced lung and tissue edema
- · 2006: Joint Theatre Trauma System Guidelines
- 2012: Joint Trauma System Clinical Practice Guidelines

Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007;62: 307–10.

The Fritsma Factor

Massive Tx Protocol 13






TIC: Massive Trauma Hematoma or Hemorrhage





Figure 2. Severely injured patients can present with coagulopathy at the time of hospital admission. This soldier arrived in hemorrhagic shock and required massive transfusion with packed red blood cells (PRBC), coagulation products, and whole blood. Tourniquets were placed on the patient's thighs in

The Fritsma Factor

Coagulopathy 15







THE FRITSMA FACTOR Your Interactive Hemostasis Resource

Lost Clotting Ability

- Half of FG and PLT pools exsanguinate and are lost in massive hematoma or hemorrhage
- · Factor VII is lost to exposed tissue factor
- · Factor V and VIII depletion
- Nerve tissue emboli from injured brain, fat emboli from broken bones, and amniotic fluid emboli in pregnancy cause DIC with defibrination
 - Especially thromboplastin-rich brain tissue





THE FRITSMA FACTOR
Your Interactive Hemostasis Resource

Coagulant Deficit Upon Arrival Injury Severity Score >16

injury coverny cools		
Clotting factors	<u>Critical</u> deficit ≤30% clotting factor activity 22 patients	
Factor II (n=105)	2 (9.1%)	
Factor V (n=105)	22 (100%)	
Factor VII (n=108)	1 (4.5%)	
Factor VIII (n=110)	4 (18.2%)	
Factor IX (n=105)	2 (10%)	
Factor X (n=96)	2 (10%)	
Factor XI (n=99)	3 (15%)	
Factor XII (n=97)	2 (10%)	

Rizoli SB, Scarpelini S, Callum J, et al. Clotting factor deficiency in early trauma-associated coagulopathy. J Trauma. 2011; 71: S427–S434

20



Clotting Factor Dilution

- Hypotension leaves plasma colloid osmotic pressure unopposed. Protein-poor fluid seeps into vasculature, diluting coagulation factors and PLTs
- · Crystalloids like 5% dextrose further dilute blood
- · Whole blood?
 - $\,-\,$ Donor whole blood is diluted with 67 mL A/C per 450 mL TV
 - Whole blood theoretical best HCT is 28%
- · Red cells?
 - Coagulation factor activity is diminished to 60%
 - PLT count averages 90,000/uL

Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodiluon. Anesthesiology 2010;113:1205–19.



Coagulopathy 21

THE FRITSMA FACTOR Your Interactive Hemostasis Resource

Hypothermia, Acidosis, Fibrinolysis

- All enzyme activity slows at <37°C
- PLT activation slows at 32-34°C (?)
- Platelets cease to bind VWF at 30°C
- Vitamin K-dependent factors II, VII, IX, and X fail to bind phospholipid in acidosis
- Thrombomodulin exposure activates & consumes protein C
- \bullet α_2 -antiplasmin loss prolongs free plasmin life
- Decreased plasminogen activator inhibitor (PAI-1) prolongs tissue plasminogen activator (TPA) life
- Thrombin consumption lowers TAFI activation
 - Thrombin-activatable fibrinolysis inhibitor
- Factor XIII dilution causes inadequate fibrin crosslinking
- Fibrin strands are thin, easily digested


 The Fritama Factor


 The Fritama Factor


 The Fritama Factor

 The Strands are thin, easily digested

Coagulopathy 22









Injury Severity Score (ISS)

,,,			
Region	Description (Examples)	Injury Score (1-6)	Highest 3 Squared
Head & neck	Cerebral contusion	3 (Serious)	9
Face	Scratches	1 (Minor)	
Chest	Sucking wound	4 (Severe)	16
Abdomen	Liver contusion Spleen rupture	2 (Moderate) 5 (Critical)	25
Extremity	Fractured femur	3 (Serious)	
External		1 (Minor)	1
Sum		ISS:	50
Mariana is 75 Historia assistant a second Committee III the 100 is			

Maximum is 75. If injury is assigned a score of 6 (unsurvivable), the ISS is automatically 75. ISS correlates linearly with mortality, morbidity and hospital stay. See also automated revised ISS, TRISS, which incorporates respiration and BP.

Baker SP, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974;14:187–96

The Fritsma Factor Coagulopathy 26



Probability of Life-threatening Coagulopathy in Trauma

n = 58, received >10 RBCs Condition:	% Coagulo- pathy*	
Injury severity score (ISS) >25 alone	10%	
ISS >25 & systolic BP <70 mm Hg	39%	
ISS >25 & body temp <34°C	49%	
ISS >25 & pH <7.10	58%	
ISS >25; SBP <70 mm Hg; body temp <34°C	85%	
ISS >25; SBP <70 mm Hg; temp <34°C; pH <7.10	98%	
*Life-threatening coagulopathy defined as PT and		

*Life-threatening coagulopathy defined as PT and PTT ≥ 2X mean of reference interval (MRI)

Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidosis revisited. J Trauma 1997;42:857–62.

e Fritsma Factor Coagulopathy 27




Coagulopathy in Trauma

% Coagulopathy by Lab Assay*
57.7%
10.9%
% Mortality
46%
10.9%
19.5%

*Coagulopathy defined independent of fluid replacement as: PT ≥18s,16.3%; PTT ≥60s, 24.4%; or thrombin time ≥15s, 14.2%

Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54: 1127–30


ritsma Factor Coagulopathy 28






Definition and "Drivers" of TIC


- · Retrospective cohort study
 - 3646 trauma patients at five international trauma centers
 - TIC = PTR >1.2; correlates with ISS and shock
- Prothrombin time ratio (PTR) >1.2
 - Mortality 22.7%Vs. 7.0%, p <0.001
 - RBC use 3.5 versus 1.2 units, p <0.001
 - Plasma use 2.1 versus
 0.8 units, p < 0.001





Frith D, et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost 2010;8:1919–25.


Coagulopathy 30











Intraoperative RBC Transfusion Risks

Start MTF

if any two are present

Massive Tx Protocol 34

Independent Outcome	RBCs	No RBCs
Sepsis	16.4%	9.8%
Pulmonary complication	12.6%	6.0%
Wound complications	9.2%	4.7%
Mortality	6.4%	4.4%
Thromboembolic disease	4.0%	1.9%
Renal complications	2.7%	1.9%
Cardiac complications	2.1%	1.4%
30-day outcomes, all but the last two significant at p < 0.05		

Glance LG, Dick AW, Mukamel DB, et al. Association between intraoperative blood transfusions and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology 2011;114:283–92.



RBC Transfusion Risks in Trauma

- Tx predicts MOF when victim survives >24 h
- · Transfusion-associated circulatory overload (TACO)
- · Tx correlates with 4X rise in ICU admission
- · Mortality rises with each RBC unit
- No patient >75 who gets >12 RBC units survives
- · Tx infection odds ratio 5.26 versus no Tx
- Composite risk of TRALI* and ARDS* 1:5000
 - *Transfusion-related acute lung injury
 - *Acute respiratory distress syndrome

Robinson WP, Ahn J, Stifler A, et al. Blood transfusion is an independent predictor of increased mortality in non-operatively managed blunt hepatic and splenic injuries. J Trauma 2005;58:437–44

The Fritsma Facto

RBCs 37



RBC Transfusion Risks in Context Transfusion-related acute lung injury Ann Intern Med. 2012;157:49–58 RBC Transfusion Risks in Context Transfusion-associated circulatory overload Fever Fine Efficience Factor Ann Intern Med. 2012;157:49–58 RBCs 38

THE FRITSMA FACTOR Your Interactive Hemostasis Resource

RBC Risks and Indications

Risk	Indication	
ABO Incompatibility*	Fever, hemoglobinuria, hemoglobinemia	
TRALI* or TACO	Respiratory distress, hypoxemia	
Bacterial contamination	Fever, hypotension	
Allergic reaction	Urticaria	
Citrate toxicity	Hypocalcemia	
1		

*Observe for delayed TRALI and Tx reaction; terminate Tx and start diagnostic tests


The Fritsma Facto

RBCs 39



Platelet Concentrate

- · Clinicians discouraged from giving platelets
 - Why? "Platelets are a precious commodity."
- Use early anyway, they stabilize the coagulopathy
 - PLT concentrate has all the "good stuff" that is in plasma



transfused trauma patients. JACS 2010.
The Fittems Factor PLTS 40



What Does "Plasma" Mean?

- Fresh frozen plasma (FFP)
 - Plasma processed and placed at ≤ –18C within 8 h of collection
 - Plasma from males or nulligravida females to avoid TRALI
 - Largely discontinued 2000–2010, though name lives on
- 24-h plasma (PF24)
 - WB ambient ≤8 h→1-6C ≤16 h→processed→ -18C in 24 h
 - Most common prep, mis-named FFP by most health care pros
- 24-h plasma (PF24RT24)
 - WB held ambient, processed and placed at –18C within 24 h
 - Approved 4/1/2014 for replacement of non-labile coagulation factors
- · All preparations stored frozen up to 12 months
- Thawed AB plasma: stored at 1–6C; 5 d if closed

The Fritsma Factor Plasma



Mean Factor V, VIII and Protein S Levels in FFP, PF24, and PF24RT24

Preparation	Factor V	Factor VIII	Protein S
FFP at thaw	85%	81%	97%
FFP 5d post-thaw	67%	43%	92%
PF24 at thaw	86%	66%	90%
PF24 5d post-thaw	59%	48%	78%
PF24RT24 at thaw	90%	86%	82%
PF24RT24 5d post-thaw	89%	86%	73%

- O'Neill EM, Rowley J, Hansson-Wicher M, et al. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999;39:488–91.
 Cardigan R, Lawrie AS, Mackie IJ, Williamson LM. The quality of fresh frozen plasma
- Cardigan R, Lawrie AS, Mackie IJ, Williamson LM. The quality of fresh frozen plasma produced from whole blood stored at 4 C overnight. Transfusion 2005;45:1342–48.

Fritsma Factor

Plasma 42

RBC/Plasma 1:1

- · USA hospital in Baghdad Green Zone
 - Tx >2000 wounded, massively Tx >600 wounded
 - Retrospective w/o controls but extensive, careful documentation
- Receiving ≤1 plasma per 4 RBCs: 65% mortality
 - Confounding data: soldiers who received >10 RBC units but died before plasma could thaw are counted in this arm
- Receiving 2 plasma for every 3 RBCs: 19% mortality
- Confounded: survivors receive more plasma Vs. those who die
 - Requires ~15 h to resolve coagulopathy
 - Surgeons report less bleeding and edema
- · Anticipated adverse effects
 - Plasma supply—yes
 - TACO—yes

 No TRALI, anaphylaxis, ARDS, MOF, or thrombosis
orgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affect mortality
alients receiving massive transfusions in a combat support hospital. J Trauma 2007; 63: 805–13. Borgman MA. Sp



ASA 2015 Plasma Indications



- · Manage preoperative or bleeding pts who require repla of multiple coagulation factors (eg, liver disease, DIC).
- Manage patients undergoing massive transfusion who have clinically significant coagulation deficiencies.
- Manage bleeding patients taking warfarin or who need an invasive procedure before vitamin K could reverse the warfarin effect (but 4-factor PCC is better).
- Transfusion or plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)
- Manage patients with congenital or acquired factor deficiencies for which there are no specific coagulation concentrates
- FP24RT24 not indicated for factor VIII or protein S deficiency

Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative
Blood Transfusion and Adjuvant Therapies. Anesthesiology 2015;22:241–75
Plasma 44



Plasma Reduces EC Permeability

- Barrier dysfunction, interstitial edema tissue hypoxia, inflammatory cells
- Infiltration, detached pericytes, extracellular matrix breakdown, apoptosis, exposed subendothelium
- · Stabilizes ECs through junction protein regulation







Crystalloids



Kozar R, Peng Z, Zhang R. Plasma restoration of endothelial glycocalys in a rodent model of hemorrhagic shock. Anes & Analgesic 2011



Group AB Plasma When ABO is Unknown

- Group AB from males & nulligravida females
 - Pre-restrictions: odds of AB plasma TRALI 14.5 X higher than A, B, or O
 - TRALI restrictions first applied 4/1/2014
 - AB = 2.6% of active donors before TRALI restriction
 - AB availability now cut by 33%
- AB demand raised
 - New massive Tx protocols raise plasma demand
 - Maintaining thawed plasma supply in ER
 - Thawed AB diverted to non-ABs on 5th day to avoid waste
- Solution: group A plasma

WHAT? Zelinski MD, Johnson PM, Jenkins D, et al. Emergency use of prethatyed gra A plasma in trauma patients. J trauma Acute Care Surg 2013; 74: 69-75.





Group A Plasma When ABO is Unknown

- Most recipients are A and O, compatible w/ A plasma
- · Anti-B titers low in TRALI-restricted population
- B substance in secretors neutralizes anti-B
- · PTs may be receiving massive O RBCs anyway
- U Mass, 2008–13 (similar data from Mayo)
 - Emergency release of 358 A plasmas
 - 84% of recipients turned out to be A or O, compatible
 - 23 recipients were B or AB, 11 of these received O RBCs
 - No acute hemolytic transfusion reactions
 - Three weak positive post-transfusion DATs
 - Reduced AB plasma usage 97%

Chhibber V, Green M, Vauthrin M, et al. Is group A plasma suitable as the first option for ememrgency release transfusion? Transfusion 2014; 54: 1751 a5ma 47




Group AB Plasma When ABO is Unknown


- · 76 U of Cincinnati PTs received 76 gendernonspecific group AB plasma transfusions, and compared to Mayo trial they had...
 - Lower ratios of arterial O₂ partial pressure to fractional inspired oxygen.
 - Higher rates of sepsis (p=0.024), acute renal failure (p = 0.003), DVT (p = 0.021), and PE (p = 0.013).
 - Longer ICU stays.


Postma K. Group A plasma: The new universal plasma for trauma patients 2015 Clin Lab Sci—in process.
Zielinski M, Johnson P. Emergency use of prethawed Group A plasma in trauma


patients. J Trauma Acute Care Surg 2013;741:69-74; discussion 74-5.

Plasma 48
















PROPPR Trial: Group A Plasma

- 12 level I trauma centers
- Balanced BPs randomized: 1:1:1 or 1:1:2
 - Plasma : platelet concentrate : red blood cells
- All but 1 center delivered 6 u universal donor plasma and 6 of UD RBCs in 10 minutes
- 3 sites provided 141 group A plasma to AB and B patients, 97 units untitered anti-B
 - No transfusion reactions

Novak DJ, Bai Y, Cooke RK, Marques MB, et al. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. Transfusion 2015; 55:1331–9.

itsma Factor Plasn



FRITSMA FACTOR Your Interactive Hemostasis

Fresh Whole Blood—Why Not?

- FWB provides plasma:RBC:PLTs in a 1:1:1 ratio
- · FWB improvsd survival compared to stored components.
- · FWB is available in austere conditions
- · No cold storage loss of clotting factor or platelet function.
- · No RBC storage lesion. Butt...
- · Lack of screening: transfusion-transmitted infections
 - HBV, HCV, HIV, HTLV, syphilis
- Grouping error and hemolytic transfusion risk
 - Crossmatch required
- Bacterial contamination

Joint Theater Trauma System Clinical Practice Guideline: Fresh whole blood transfusion, 2012

The Fritsma Factor

57



Tranexamic Acid (Cyclokapron) Rx

Cyclohexane

carboxylic acid

 Synthetic lysine blocks plasminogen binding sites, reduces fibrinolysis

 Reduces Tx requirements in surgery without raising mortality

· Around since 1968, cheap

CRASH-2 trial collaborators (570). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. The Lancet 2010; 376: 23-32

The Fritsma Factor



COOH

NH₂

.,,,

THE FRITSMA FACTOR Your Interactive Hemostasis Resource

Tranexamic Acid Death by Cause

CRASH-2	IV TXA	Placebo	RR	р
1 g TXA bolus + 1 g/8h	n = 10060	n = 10067		
Any cause of death	1463 (14.5%)	1613 (16%)	0.91	0.0035
Bleeding death	489 (4.9%)	574 (5.7%)	0.85	0.0077
Thrombosis death	33 (0.3%)	48 (0.5%)	0.69	0.096
No significant differences in accompatibility and study. VTD				

No significant differences in myocardial infarct, stroke, VTE, blood product volumes


Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet 2010; 376:23–32.

The Eritema Earth

TXA 59



All-cause Mortality by Subgroup Tranexamic Acid Versus Placebo



THE FRITSMA FACTOR Your Interactive Hemostasis Resource

CRASH 2 on Public Media Use TXA, CRYO, and PCC

- · Rapid, effective, predictable rise in factor activity
- · Activated PCC, 4-factor PCC; low volume vs. plasma
- RiaSTAP® FG; low volume vs. CRYO, no TACO
- Avoid 58% of massive transfusions
 "Massive transfusion avoidance protocol"
- · No risk of incompatible transfusion
- Reduce plasma Tx by 90%
- · Effective viral inactivation
- Reduce RBC Tx by 8.4%
- No risk of TRALI
- "Never" use rVIIa?

 The Fritsma Factor

 T



THE FRITSMA FACTOR Your Interactive Hemostasis Resource

CRASH-2 Weaknesses

- · Subject selection based upon "uncertainty" principle
- Most subjects in countries with austere trauma care
 Benefits could be lost in mature facilities with BBP protocols
- No laboratory monitoring: TEG, TEM
- · TXA antifibrinolytic mechanism poorly defined
- No effort to measure thrombosis except for death
 Other studies report 13% DVT/PE prevalence in TXA Rx
- · Small subject cohort who required blood
 - Blood product usage equivalent in TXA and control arm
- · Several new trials in progress
- MATTER reported better outcomes than CRASH-2
 - Number needed to treat: 7 versus 67

Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military application of tranexamic acid in trauma emergency resuscitation (MATTER) study. Arch Surg 2012;147: 113–19.

